RPL34抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: A375 cell lysate, Primary antibody: P02975(RPL34 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P02975(RPL34 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The RPL34 antibody is a research tool designed to detect ribosomal protein L34 (RPL34), a component of the 60S ribosomal subunit. Ribosomal proteins like RPL34 play essential roles in protein synthesis, ribosome assembly, and cellular homeostasis. RPL34 is evolutionarily conserved and contributes to the structural stability of the ribosome, facilitating interactions between rRNA and other ribosomal proteins. Dysregulation of ribosomal proteins, including RPL34. has been implicated in diseases such as cancer, where altered ribosome biogenesis ("ribosomopathies") may drive tumor progression or metastasis.

Antibodies targeting RPL34 are typically developed using immunogens derived from specific epitopes of the human RPL34 protein. These antibodies are validated for applications like Western blotting, immunofluorescence, and immunohistochemistry to study RPL34 expression, localization, and potential overexpression in pathological conditions. Some studies suggest RPL34 may serve as a biomarker in certain cancers, though its mechanistic role remains under investigation. Cross-reactivity with homologs in model organisms (e.g., mice, rats) is common due to high sequence conservation. Researchers often employ these antibodies to explore links between ribosomal dysfunction, cellular stress responses, and disease pathways. Validation steps, such as siRNA knockdown or knockout cell controls, are critical to confirm specificity given the shared homology among ribosomal proteins.